Michael Polcari, MD
Allergy & Immunology · Birmingham, ALNPI 1568807378
Payments from drug & device makers
Across 866 payments — averaging $99.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$30K
- GSK$22K
- Astrazeneca UK Limited$16K
- Vanda Pharmaceuticals Inc.$5K
- CSL Behring$2K
- Sanofi$2K
- plus $10K from 33 others
What the payments were for
- Speaking & faculty fees$19,82551%
- Grants$7002%
- Travel & lodging$920%
- Food & beverage$17,91746%
- Education$1560%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 109 | $29,907 |
| GSK | 122 | $21,832 |
| Astrazeneca UK Limited | 1 | $15,500 |
| Vanda Pharmaceuticals Inc. | 1 | $4,500 |
| CSL Behring | 85 | $2,482 |
| Sanofi | 47 | $1,742 |
| Regeneron Healthcare Solutions, Inc. | 65 | $1,581 |
| Genentech USA, Inc. | 59 | $1,427 |
| Takeda Pharmaceuticals U.S.A., Inc. | 55 | $1,242 |
| Optinose US, Inc. | 54 | $890 |
| Novartis | 55 | $820 |
| Blueprint Medicines Corporation | 28 | $744 |
| Amgen | 38 | $616 |
| Pfizer | 30 | $547 |
| LEO Pharma Inc. | 25 | $536 |
| Grifols USA, LLC | 15 | $297 |
| Pharming Healthcare, Inc. | 9 | $166 |
| GC Biopharma USA, Inc. | 8 | $166 |
| Organon | 7 | $148 |
| Kaleo, Inc. | 9 | $141 |
| ARS Pharmaceuticals Operations, Inc. | 6 | $135 |
| Lilly USA, LLC | 6 | $128 |
| Genentech, Inc. | 1 | $88 |
| Biocryst US Sales Co., LLC | 3 | $70 |
| Insmed, Inc. | 2 | $65 |
| Cycle Pharmaceuticals Inc | 3 | $65 |
| Mylan Specialty L.p. | 3 | $52 |
| AbbVie | 3 | $49 |
| Teva Pharmaceuticals USA, Inc. | 4 | $48 |
| Paratek Pharmaceuticals, Inc. | 3 | $44 |
| ADMA Biomanufacturing LLC | 2 | $26 |
| Alk-abello, Inc | 1 | $23 |
| Ionis Pharmaceuticals, Inc. | 1 | $23 |
| Galderma Laboratories, L.p. | 1 | $18 |
| Hikma Pharmaceuticals USA | 1 | $15 |
| Eyevance Pharmaceuticals LLC | 1 | $14 |
| Merck | 1 | $14 |
| Incyte Corporation | 1 | $14 |
| Shire North American Group Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$86,190 in reported general payments places this provider in the 75th percentile of 30 allergy & immunology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HaegardaC1 Esterase Inhibitor | 14 | $787,830 |
| Dupixent PenDupilumab | 116 | $424,035 |
| XolairOmalizumab | 59 | $208,927 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 183 | $168,817 |
| Dupixent SyringeDupilumab | 41 | $151,836 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 20 | $144,743 |
| TezspireTezepelumab-Ekko | 21 | $86,550 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 16 | $75,440 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 48 | $36,414 |
| DuleraMometasone/Formoterol | 45 | $22,908 |
| Spiriva RespimatTiotropium Bromide | 22 | $18,142 |
| Tacrolimus | 51 | $11,947 |
| Epinephrine | 49 | $10,772 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $7,857 |
| Cyclosporine | 19 | $6,813 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringHaegarda, Hizentra | $2,482 | $932,57334 claims |
| Genentech, Inc.Xolair | $88 | $208,92759 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $21,832 | $179,996213 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $29,907 | $125,48981 claims |
| Grifols USA, LLCGamunex-C | $297 | $75,44016 claims |
| MerckDulera | $14 | $22,90845 claims |
| Hikma Pharmaceuticals USAEpinephrine | $15 | $10,77249 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 30 allergy & immunology providers in Alabama.
Other allergy & immunology in Birmingham
- Njeri MainaBirmingham$241K
- Thomas AtkinsonBirmingham$155K
- Miranda CurtissBirmingham$46K
- Carol SmithBirmingham$11K
- Amy CajacobBirmingham$8K
- Tracy HwangpoBirmingham$5K
- William MasseyBirmingham$3K
- Elizabeth GeorgeBirmingham$3K
- Kathleen GrisantiBirmingham$1K
- John AndersonHomewood$3.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.